R&D channel feed – Endpoints News

R&D channel feed

Updated: Weaker Omicron variant is great news for the world, but bad news for Covid-related clinical trials

4 years ago

FDA slaps hold on Finch's microbiome C. difficile treatment, as biotech blames Covid-19 and old manufacturer

4 years ago

Novavax doubles down on promise to produce 2B Nuvaxovid doses — this year

4 years ago

Pfizer joins Sanofi on the C. difficile failure train after its vaccine flopped a PhIII study

4 years ago

Epizyme joins the queue of biotechs now handing out pink slips, conserving cash

4 years ago

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

4 years ago

Expanded Intellia CRISPR data set up showdown with Pfizer, Ionis and Alnylam in not-so-rare disease

4 years ago

Sanofi, Regeneron build their case for yet another approval for immunology star Dupixent

4 years ago

As Eli Lilly steams ahead with a closely-watched BTK drug, its rivals at Merck are taking a $275M write-down on delay

4 years ago

Safety concerns cause GSK to stop highly anticipated vaccine trial in surprise setback

4 years ago

Another burned-out SPAC biotech raises the white flag as CEO departs, strategic review begins

4 years ago

In latest setback for solid tumor CAR-T, Celyad pauses trial following two patient deaths

4 years ago

Russian invasion of Ukraine threatens hundreds of clinical trials

4 years ago

For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects

4 years ago

AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

4 years ago

Tillman Gerngross makes it official: He's out as CEO as troubled Adagio vows to soldier on

4 years ago

Bayer oncology vet Robert LaCaze has his eyes on next steps — landing his first gig as CEO of Sadelain co-founded biotech

4 years ago

Sanofi, GSK prep regulatory filings for Covid-19 vaccine after posting PhIII, booster data — but who will use it?

4 years ago

Kodiak’s Eylea contender falls flat in PhIII, wiping out nearly $2B in value

4 years ago

Tiny pharma hits a new low with FDA refusing to review company's response to its CRL

4 years ago

Lilly breaks the bank on the potential for RNA with $700M investment in Boston's Seaport

4 years ago

Biotech shares eviscerated in wake of Covid-19 flop

4 years ago

Claiming historic first, AstraZeneca says Enhertu aces PhIII for hard-to-reach segment of patients

4 years ago

As Moderna adds on a host of new commercial subs, there's room for 3 more vaccine candidates in the pipeline

4 years ago

First page Previous page 145 146 147148149 150 151 Next page Last page